Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA)

Tuesday, November 9, 2021 1 min read

Key Takeaway: Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA)

Full Press Release Details

Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA).